The “STING Pathway Targeting Therapeutics and Technologies, 2020-2030
To order this detailed 310+ page report, please visit this -https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
Key Inclusions
§ A detailed assessmentof the current market landscape of therapeutics targeting STING pathway, basedon several parameters, such as type of STING modulator (agonist or antagonist),type of molecule (small molecules, cyclic dinucleotides, non-nucleotides,biologics and others), phase of development (discovery, preclinical andclinical), target therapeutic area(s), type of therapy (monotherapy andcombination therapy), route of administration (intratumoral, intravenous andothers), and line of treatment (last line, second line or greater and firstline or greater). The chapter also features an analysis of the developerlandscape (including information on year of establishment, company size,geography and most active players). Further the chapter includes an analysis onthe clinical trials focused on STING, along with information on parameters,such as recruitment status, study design and clinical endpoints.
§ A detailed chapterhighlighting various technology platforms that are being actively used for thedevelopment of STING modulators and analysis based on several parameters, suchas type of modulator (agonist or antagonist), type of molecule (smallmolecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics,nanoparticles and synthetic peptides), and analysis based on technologydeveloper landscape (including information on year of establishment, companysize and geography).
§ Elaborate profiles ofkey players that are engaged in the development of therapeutics targeting STINGpathway (shortlisted on the basis of phase of development of pipelineproducts), featuring a brief overview of the company, its financial information(if available), detailed descriptions of their respective lead drug candidates,recent developments and an informed future outlook. Additionally, each drugprofile features information on the type of drug, route of administration,target indications and current status of development.
§ Tabulated profiles ofindustry players (shortlisted on the basis of the antagonist in pipelineproducts), featuring details on the innovator company (such as year ofestablishment, location of headquarters, number of employees, key members ofthe executive team and recent developments), along with descriptions of theirrespective drug candidates.
§ A study on variousgrants that have been awarded to research institutes engaged in projectsrelated to STING pathway, during the period 2015 - Q1 2020, based on multipleparameters, such as number of grants awarded, amount awarded, fundinginstitute, support period, funding mechanism, type of grant application, grantactivity code, most popular NIH department, type of recipient organization,regional distribution, most popular recipient organization(s), prominentproject leader(s) and study section. It also includes an analysis of on grantattractiveness.
§ An analysis of bigpharma players engaged in the development of therapeutics targeting STINGpathway, based on several parameters, such as portfolio diversity, type ofmolecule, phase of development, therapeutic area(s), type of therapy and routeof administration. In addition, the chapter features a benchmarking analysis ofthe aforementioned players.
§ An analysis of thestart-ups / small players (established in the last ten years, less than 50employees) engaged in the development of therapeutics targeting STING pathway,based on several relevant parameters, such as portfolio diversity, type ofmolecule, phase of development, therapeutic area, funding received, number ofinvestors, type of funding, partnership activity, number of patents filed,grants received, and start-up health indexing.
§ A detailedpublication analysis of more than 300 peer-reviewed, scientific articles thathave been published during the period 2019 - Q1 2020, highlighting the researchfocus within the industry. It also highlights the key trends observed acrosspublications, including information on type of publication, year ofpublication, study objective, popular keywords, type of STING modulator, targetpathway, therapeutic area, type of publisher, leading players (in terms ofnumber of publications), region, first author organization and key journals (interms of number of articles published in this domain).
§ An analysis of thepartnerships that have been established in the domain, over the period 2015 -Q1 2020, covering research agreements, product / technology licensingagreements, mergers / acquisitions, R&D and commercialization agreements, IP licensing agreements,clinical trial agreements, product development agreements, and other relevantdeals. The chapter highlights analysis based on year of partnerships, type ofpartnership model, type of STING modulator, therapeutic area, technologyplatform, most active player(s) (in terms of number of partnerships inked), andregion.
§ An analysis of theinvestments made at various stages of development, such as seed financing,venture capital financing, debt financing, grants / awards, capital raised fromIPOs and subsequent offerings, by companies engaged in this field. The chapterhighlights analysis based on the number of funding instances, amount invested,type of funding, type of STING modulator, therapeutic area, technologyplatform, most active player(s) (in terms of number of funding instances), mostactive investor(s) (in terms of number of funding instances) and geographicalregion.
The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:
§ Types of Payment
§ Upfront Payments
§ Milestone Payments
§ Type of STING Modulator
§ Agonist
§ Antagonist
§ Key Therapeutic Area(s)
§ Oncological Disorders
§ Inflammatory Disorders
§ Infectious Diseases
§ Others
§ Route of Administration
§ Intratumoral
§ Intravenous
§ Oral
§ Subcutaneous
§ Others
§ Type of Molecule
§ Non-nucleotide
§ Cyclic Dinucleotide
§ Live Biotherapeutics
§ Oncolytic Peptides
§ Synthetic Peptides
§ Others
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market/request-sample.html
KeyQuestions Answered
§ Whoare the leading developers of STING pathway targeting therapeutics andaffiliated technologies?
§ Whatare the most popular STING pathway related technology platforms in the market?
§ Whatare the key therapeutic areas for which STING pathway targeting therapeuticsare being / have been developed?
§ Whatkind of partnership models are commonly adopted by stakeholders engaged in thisindustry?
§ Whatis the trend of capital investment for STING pathway targeting therapeutics andtechnologies?
§ How is the current and futureopportunity likely to be distributed across key market segments in this domain?
You may also be interested in the following titles:
1. Nuclear Medicine andRadiopharmaceuticals Manufacturing Market, 2020-2030
2. GlobalPsychedelic Therapeutics Market by Type ofPsychedelic Substance (Ketamine, Psilocybin, MDMA and Others), by Origin(Natural and Synthetic), by Type of Therapy (Monotherapy, Combination andOthers), by Route of Administration (Oral, Intravenous, Intranasal and Others)and by Key Geographies (North America, Europe and Asia- Pacific and rest of theworld): Industry Trends and Global Forecasts, 2020-2030
3. EndocannabinoidSystem Targeted TherapeuticsMarket, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
